Cargando…

A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma

BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-Tao, Xia, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344165/
https://www.ncbi.nlm.nih.gov/pubmed/30608388
http://dx.doi.org/10.1097/MD.0000000000013779
_version_ 1783389391797878784
author Wang, Hai-Tao
Xia, Ming
author_facet Wang, Hai-Tao
Xia, Ming
author_sort Wang, Hai-Tao
collection PubMed
description BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). However, there have been conflicting results across the trials that evaluated the efficacy of sorafenib. OBJECTIVE: The aim of the study was to perform a meta-analysis to compare the efficacy and safety of sorafenib in first-line treatments of mRCC. METHODS: We searched online electronic databases: PubMed, Embase, and the Cochrane Library updated on September 2017. Trials on the efficacy of sorafenib in first-line treatments of advanced RCC were included, of which the primary outcomes were objective response rate (ORR), PFS, overall survival (OS), and grade 3/4 adverse events (AEs). RESULTS: A total of 5 trials were included in this analysis. The group of AEs showed significantly improved PFS (odds ratio [OR] = 0.78, 95% confidence interval [CI] = 0.70–0.86, P < .001), as well with the ORR (OR = 1.89, 95%CI = 1.38–2.59, P < .0001) compared with sorafenib. However, there was no significant difference in OS (OR = 0.97, 95%CI = 0.78–1.22, P = .82). CONCLUSION: Sorafenib did not achieve efficacy and safety benefit in patients with mRCC compared with those treated with TAs. The role of sorafenib in first-line treatments of mRCC may change in favor of newer drugs. More research is needed to confirm whether these new TAs could replace sorafenib as the gold standard in the future.
format Online
Article
Text
id pubmed-6344165
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63441652019-02-04 A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma Wang, Hai-Tao Xia, Ming Medicine (Baltimore) Research Article BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). However, there have been conflicting results across the trials that evaluated the efficacy of sorafenib. OBJECTIVE: The aim of the study was to perform a meta-analysis to compare the efficacy and safety of sorafenib in first-line treatments of mRCC. METHODS: We searched online electronic databases: PubMed, Embase, and the Cochrane Library updated on September 2017. Trials on the efficacy of sorafenib in first-line treatments of advanced RCC were included, of which the primary outcomes were objective response rate (ORR), PFS, overall survival (OS), and grade 3/4 adverse events (AEs). RESULTS: A total of 5 trials were included in this analysis. The group of AEs showed significantly improved PFS (odds ratio [OR] = 0.78, 95% confidence interval [CI] = 0.70–0.86, P < .001), as well with the ORR (OR = 1.89, 95%CI = 1.38–2.59, P < .0001) compared with sorafenib. However, there was no significant difference in OS (OR = 0.97, 95%CI = 0.78–1.22, P = .82). CONCLUSION: Sorafenib did not achieve efficacy and safety benefit in patients with mRCC compared with those treated with TAs. The role of sorafenib in first-line treatments of mRCC may change in favor of newer drugs. More research is needed to confirm whether these new TAs could replace sorafenib as the gold standard in the future. Wolters Kluwer Health 2019-01-04 /pmc/articles/PMC6344165/ /pubmed/30608388 http://dx.doi.org/10.1097/MD.0000000000013779 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Wang, Hai-Tao
Xia, Ming
A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title_full A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title_fullStr A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title_full_unstemmed A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title_short A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
title_sort meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344165/
https://www.ncbi.nlm.nih.gov/pubmed/30608388
http://dx.doi.org/10.1097/MD.0000000000013779
work_keys_str_mv AT wanghaitao ametaanalysisofefficacyandsafetyofsorafenibversusothertargetedagentsformetastaticrenalcellcarcinoma
AT xiaming ametaanalysisofefficacyandsafetyofsorafenibversusothertargetedagentsformetastaticrenalcellcarcinoma
AT wanghaitao metaanalysisofefficacyandsafetyofsorafenibversusothertargetedagentsformetastaticrenalcellcarcinoma
AT xiaming metaanalysisofefficacyandsafetyofsorafenibversusothertargetedagentsformetastaticrenalcellcarcinoma